Advertisement: RSM mid banner
Advertisement: Excalibur Healthcare mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: TTP
Barr Ellison Solicitors – commercial property
Mid banner advertisement: BDO
Advertisement: partnersand mid banner
Advertisement: CJBS mid banner
Advertisement: S-Tech mid banner 3
Advertisement: EBCam mid banner
ARM Innovation Hub
Advertisement: Cambridge Network mid banner
Advertisement: HCR Hewitsons recruitment mid banner
Advertisement: Wild Knight Vodka
Advertisement: Simpsons Creative
Advertisement: Mogrify mid banner
25 June, 2015 - 16:57 By Tony Quested

SyndicateRoom delivers fertile growth opportunity to investors

Goncalo De Vasconcelos CEO at SyndicateRoom

Cambridge equity crowdfunding platform SyndicateRoom has proved fertile territory for a UK company seeking to raise £275k growth capital.

Fertility Focus has devised a home test device that it claims delivers world-leading, 99 per cent accuracy on exactly when to conceive. 

The expectant company has already raised 77 per cent of its target – £213k – and that looks like being handsomely surpassed by the final investment deadline on Sunday, July 5.

Fertility Focus claims that its OvuSense devise is literally pregnant with possibilities as it uses real-time ovulation monitoring to take the guesswork out of when to try for a baby. It claims to be able to precisely predict the onset of ovulation a day in advance and confirm the exact time and date when it occurs. 

By early 2016 the company will seek a further £1 million-plus from an institutional investor, when it expects the price to exceed £35 per share. The company predicts an exit value in excess of £60m from a current valuation of £4m, offering investors in this round a potential return worth ten times their investment.

Fertility Focus chairman, Steve Godber, said: “It is not a matter of whether Fertility Focus will deliver a return to shareholders – it is just a question of when and how much.” 

The investment could significantly benefit the 30 per cent of all women who have ovulatory issues that are undetectable at home and often missed by doctors, as well as the 24 million women worldwide seeking online advice for fertility problems, such as those caused by polycystic ovarian syndrome (PCOS). 

OvuSense is already on the market in Europe and the US with all the necessary regulatory approvals. It has five clinical publications and a portfolio of six patents that confer compelling competitive advantages. 
The additional investment will enable Fertility Focus to accelerate the launch of its next generation OvuSense product at a much lower price point and extend international sales and marketing for its powerful multi-language, multi-currency e-commerce platform. 

Targeted digital marketing is already driving 9,000 new visitors a month to the OvuSense website. The extra investment is intended to boost visitor rates twentyfold and convert 300 per cent more visits to sales via a more affordable monthly subscription model, in turn allowing rapid margin and EBIT growth.

Goncalo De Vasconcelos (pictured above), CEO at SyndicateRoom said: “This is a rare opportunity to invest in a proven product with strong sales traction and a robust global growth strategy.

“The team has world-class expertise in consumer digital marketing, high-volume medical devices, women’s health and intellectual property development. The CEO, chairman and lead angel investor each have several successful sector exits behind them.” 

Newsletter Subscription

Stay informed of the latest news and features